Travere Therapeutics, Inc.
TVTX· Nasdaq
TVTXTravere Therapeutics, Inc.
Filed Feb 23, 2023 · 10-K · 54 days after period end · 0001438533-23-000008
| Metric | Q4 2022 | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 |
|---|---|---|---|---|
| Revenue | $29.34M | — | $50.98M | $46.69M |
| Net Income | -$65.82M | -$51.57M | -$121.62M | -$30.26M |
| EPS Diluted | -$1.03 | — | -$2.37 | -$0.70 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
ended Dec 31, 2022 · filed Feb 23, 2023 · 54 d after period end
